X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs LUPIN LTD - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD LUPIN LTD BIOCON LTD/
LUPIN LTD
 
P/E (TTM) x 92.4 28.3 326.8% View Chart
P/BV x 7.8 3.0 264.8% View Chart
Dividend Yield % 0.1 0.6 26.3%  

Financials

 BIOCON LTD   LUPIN LTD
EQUITY SHARE DATA
    BIOCON LTD
Mar-18
LUPIN LTD
Mar-18
BIOCON LTD/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs1,1881,465 81.1%   
Low Rs305727 41.9%   
Sales per share (Unadj.) Rs68.7349.6 19.7%  
Earnings per share (Unadj.) Rs7.65.6 135.9%  
Cash flow per share (Unadj.) Rs14.029.6 47.2%  
Dividends per share (Unadj.) Rs1.005.00 20.0%  
Dividend yield (eoy) %0.10.5 29.4%  
Book value per share (Unadj.) Rs86.3300.3 28.8%  
Shares outstanding (eoy) m600.00452.08 132.7%   
Bonus/Rights/Conversions ISESOPS-  
Price / Sales ratio x10.93.1 346.5%   
Avg P/E ratio x98.9197.2 50.1%  
P/CF ratio (eoy) x53.437.1 144.2%  
Price / Book Value ratio x8.63.6 236.9%  
Dividend payout %13.290.0 14.7%   
Avg Mkt Cap Rs m447,900495,502 90.4%   
No. of employees `0006.117.0 36.1%   
Total wages/salary Rs m9,31128,647 32.5%   
Avg. sales/employee Rs Th6,705.89,273.6 72.3%   
Avg. wages/employee Rs Th1,514.21,681.0 90.1%   
Avg. net profit/employee Rs Th736.9147.4 499.8%   
INCOME DATA
Net Sales Rs m41,234158,042 26.1%  
Other income Rs m2,0621,504 137.1%   
Total revenues Rs m43,296159,545 27.1%   
Gross profit Rs m8,29131,475 26.3%  
Depreciation Rs m3,85110,859 35.5%   
Interest Rs m6152,044 30.1%   
Profit before tax Rs m5,88720,076 29.3%   
Minority Interest Rs m213-71 -300.4%   
Prior Period Items Rs m035 0.0%   
Extraordinary Inc (Exp) Rs m0-14,644 0.0%   
Tax Rs m1,5692,885 54.4%   
Profit after tax Rs m4,5312,513 180.3%  
Gross profit margin %20.119.9 101.0%  
Effective tax rate %26.714.4 185.5%   
Net profit margin %11.01.6 691.2%  
BALANCE SHEET DATA
Current assets Rs m41,486122,095 34.0%   
Current liabilities Rs m21,41350,956 42.0%   
Net working cap to sales %48.745.0 108.1%  
Current ratio x1.92.4 80.9%  
Inventory Days Days6485 75.6%  
Debtors Days Days94120 78.5%  
Net fixed assets Rs m50,661129,876 39.0%   
Share capital Rs m3,000904 331.8%   
"Free" reserves Rs m48,808134,866 36.2%   
Net worth Rs m51,808135,771 38.2%   
Long term debt Rs m17,89864,245 27.9%   
Total assets Rs m99,897263,054 38.0%  
Interest coverage x10.610.8 97.7%   
Debt to equity ratio x0.30.5 73.0%  
Sales to assets ratio x0.40.6 68.7%   
Return on assets %5.21.7 297.4%  
Return on equity %8.71.9 472.6%  
Return on capital %9.63.7 259.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,05853,141 22.7%   
Fx outflow Rs m7,34819,335 38.0%   
Net fx Rs m4,71033,807 13.9%   
CASH FLOW
From Operations Rs m6,62117,512 37.8%  
From Investments Rs m-6,840-14,073 48.6%  
From Financial Activity Rs m-2,397-14,921 16.1%  
Net Cashflow Rs m-2,612-11,482 22.7%  

Share Holding

Indian Promoters % 40.4 46.6 86.7%  
Foreign collaborators % 20.6 0.2 10,300.0%  
Indian inst/Mut Fund % 8.4 11.3 74.3%  
FIIs % 10.7 31.9 33.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 10.1 197.0%  
Shareholders   109,995 98,259 111.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   ELDER PHARMA  FDC LTD.  SHASUN PHARMA  STRIDES SHASUN LTD  TTK HEALTHCARE  

Compare BIOCON LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Stock Market's Sudden Crash; Rising Oil Prices; Banking Stocks and Top Cues in Action Today(Pre-Open)

The Indian share markets ended lower on Friday. The S&P BSE Sensex partially recovered after crashing 1,000 points in intraday trade to settle 280 points lower.

Related Views on News

LUPIN LTD 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of LUPIN LTD for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of LUPIN LTD. Also includes updates on the valuation of LUPIN LTD.

LUPIN LTD Announces Quarterly Results (1QFY19); Net Profit Up 21.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, LUPIN LTD has posted a net profit of Rs 4 bn (up 21.3% YoY). Sales on the other hand came in at Rs 26 bn (up 3.2% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Sep 21, 2018 (Close)

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE BIOCON LTD WITH

MARKET STATS